205 related articles for article (PubMed ID: 21697335)
1. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists.
Kawatkar SP; Yan M; Gevariya H; Lim MY; Eisold S; Zhu X; Huang Z; An J
Exp Biol Med (Maywood); 2011 Jul; 236(7):844-50. PubMed ID: 21697335
[TBL] [Abstract][Full Text] [Related]
2. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
Zhou N; Luo Z; Luo J; Hall JW; Huang Z
Biochemistry; 2000 Apr; 39(13):3782-7. PubMed ID: 10736178
[TBL] [Abstract][Full Text] [Related]
3. Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor.
Planesas JM; Pérez-Nueno VI; Borrell JI; Teixidó J
J Mol Graph Model; 2015 Jul; 60():1-14. PubMed ID: 26080355
[TBL] [Abstract][Full Text] [Related]
4. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
Choi WT; Tian S; Dong CZ; Kumar S; Liu D; Madani N; An J; Sodroski JG; Huang Z
J Virol; 2005 Dec; 79(24):15398-404. PubMed ID: 16306611
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists.
Gupta SK; Pillarisetti K; Thomas RA; Aiyar N
Immunol Lett; 2001 Aug; 78(1):29-34. PubMed ID: 11470148
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies.
Zhou N; Luo Z; Luo J; Liu D; Hall JW; Pomerantz RJ; Huang Z
J Biol Chem; 2001 Nov; 276(46):42826-33. PubMed ID: 11551942
[TBL] [Abstract][Full Text] [Related]
8. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.
Gerlach LO; Skerlj RT; Bridger GJ; Schwartz TW
J Biol Chem; 2001 Apr; 276(17):14153-60. PubMed ID: 11154697
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.
Rosenkilde MM; Gerlach LO; Jakobsen JS; Skerlj RT; Bridger GJ; Schwartz TW
J Biol Chem; 2004 Jan; 279(4):3033-41. PubMed ID: 14585837
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
Wong RS; Bodart V; Metz M; Labrecque J; Bridger G; Fricker SP
Mol Pharmacol; 2008 Dec; 74(6):1485-95. PubMed ID: 18768385
[TBL] [Abstract][Full Text] [Related]
11. Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.
Zhang C; Du C; Feng Z; Zhu J; Li Y
Chem Biol Drug Des; 2015 Feb; 85(2):119-36. PubMed ID: 24923360
[TBL] [Abstract][Full Text] [Related]
12. Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.
Das D; Maeda K; Hayashi Y; Gavande N; Desai DV; Chang SB; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2015 Apr; 59(4):1895-904. PubMed ID: 25583709
[TBL] [Abstract][Full Text] [Related]
13. Critical role in CXCR4 signaling and internalization of the polypeptide main chain in the amino terminus of SDF-1α probed by novel N-methylated synthetically and modularly modified chemokine analogues.
Dong CZ; Tian S; Choi WT; Kumar S; Liu D; Xu Y; Han X; Huang Z; An J
Biochemistry; 2012 Jul; 51(30):5951-7. PubMed ID: 22779681
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
[TBL] [Abstract][Full Text] [Related]
15. Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.
Thiele S; Mungalpara J; Steen A; Rosenkilde MM; Våbenø J
Br J Pharmacol; 2014 Dec; 171(23):5313-29. PubMed ID: 25039237
[TBL] [Abstract][Full Text] [Related]
16. Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12).
Veldkamp CT; Seibert C; Peterson FC; Sakmar TP; Volkman BF
J Mol Biol; 2006 Jun; 359(5):1400-9. PubMed ID: 16725153
[TBL] [Abstract][Full Text] [Related]
17. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site.
Boulais PE; Dulude D; Cabana J; Heveker N; Escher E; Lavigne P; Leduc R
Biochem Pharmacol; 2009 Dec; 78(11):1382-90. PubMed ID: 19631193
[TBL] [Abstract][Full Text] [Related]
18. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulations on SDF-1alpha: binding with CXCR4 receptor.
Huang X; Shen J; Cui M; Shen L; Luo X; Ling K; Pei G; Jiang H; Chen K
Biophys J; 2003 Jan; 84(1):171-84. PubMed ID: 12524273
[TBL] [Abstract][Full Text] [Related]
20. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities.
Brelot A; Heveker N; Montes M; Alizon M
J Biol Chem; 2000 Aug; 275(31):23736-44. PubMed ID: 10825158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
